Clinical trials in diffuse large B cell lymphoma

The table below shows a list of The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.

If you would like to know how to access our trials please click here

 

Trial Name

 

Description

 

Click the link for more information (external page)

 

GEN3013

 

Phase 1/2 study using antibody GEN3013 to target CD20- expressing cells in patients with B cell non Hodgkin lymphoma


Suitable for patients with B cell non-Hodgkin lymphoma which has come back after previous treatment

 

 

JCAR017

 

        

         Phase 2 study determining efficacy and safety of JCAR017

         Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

 

GO29781

 

A phase 1/1b trial testing mosunetuzumab, on its own or with atezolizumab

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

GCT3013-02

 

A phase 1b/2 trial of a targeted treatment, epcoritamab, in combination with different chemotherapy regimens, in people with B-cell non-Hodgkin lymphoma.

 

 

 

LOTIS-3

 

A phase 1/2 trial of loncastuximab tesirine and ibrutinib in people with relapsed or refractory diffuse large B-cell lymphoma or mantle cell lymphoma.

 

 

 

LOTIS-5

 

A phase 3 trial of loncastuximab tesirine and rituximab Vs standard immunochemotherapy in people with relapsed of refractory diffuse large B-cell lymphoma.

 

 

Sign up link will be added soon

 

GCT3013-05

 

A phase 3 trial of epcoritamab Vs standard chemotherapy in people with relapsed or refractory diffuse large B-cell lymphoma.

 

 

Sign up link will be added soon

 

 

 

A phase 3 trial of tafasitamab plus lenalidomide in addition to R-CHOP Vs R-CHOP in people with untreated high-risk diffuse large B-cell lymphoma.

 

 

Sign up link will be added soon

REMoDL-A

 

A phase 2 trial

 

 

Sign up link will be added soon

With special thanks to the following:

Last updated: October 2021